All News
Filter News
Found 1,634 articles
-
Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer Summit
2/22/2024
Medivir AB announced that clinical pharmacokinetic data on dose linearity and systemic exposure from the first study with fostroxacitabine bralpamide will be presented at the European Association for the Study of the Liver Liver Cancer Summit on February 23, 2024, in Rotterdam.
-
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
2/21/2024
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.
-
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
2/20/2024
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of B7-H3 targeting ADC (R&D code: 7MW3711) for advanced malignant solid tumor was approved by the U.S. Food and Drug Administration (FDA).
-
Medivir AB - Year-End Report January - December 2023
2/15/2024
The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months.
-
ELREXFIO is authorized by Health Canada for adults with relapsed or refractory multiple myeloma in Canada
2/13/2024
Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIO (elranatamab solution for injection).
-
Biopharma’s latest earnings season was, in a word, predictable. Companies are consistently beating Wall Street earnings and revenue estimates as they set low expectations for investors.
-
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
2/6/2024
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+.
-
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
2/2/2024
Shanghai Junshi Biosciences Co., Ltd announced that the Singapore Health Sciences Authority had accepted the New Drug Application for toripalimab, both in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
-
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
2/2/2024
Regeneron Pharmaceuticals, Inc. announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma who have progressed after at least three prior therapies.
-
VenomAid Extends Its Seed Round to a Total of $ 1.8 M for Affordable and Rapid Snakebite Diagnostics
1/30/2024
VenomAid Diagnostics, the Danish company developing snakebite diagnostics, announced that it has successfully extended its seed round to $1.8 million with continued support from a select group of private Business Angels and the philanthropic venture fund Good Ventures LLC.
-
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
1/24/2024
This first-in-man trial conducted by Onward Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bispecific antibody generated from Biomunex' proprietary BiXAb® platform.
-
First Myeloma Patient Treated with CAR-T Successfully Discharged
1/23/2024
In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion.
-
Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy
1/23/2024
Locus Biosciences, Inc. today announced the release of $23.9 million from the Biomedical Advanced Research and Development Authority (BARDA) to continue the development of Locus’ CRISPR-enhanced bacteriophage therapy, LBP-EC01, for treating urinary tract infections (UTIs) caused by drug-resistant Escherichia coli (E. coli) based on positive results from a Phase 2a clinical trial.
-
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
1/18/2024
Shanghai Junshi Biosciences Co., Ltd announced the publication of results from the prespecified interim analysis for event-free survival in patients with stage III non-Small Cell Lung Cancer of NEOTORCH in theJournal of the American Medical Association.
-
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment
1/17/2024
Ratio Therapeutics Inc. today announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million.
-
Fostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI Symposium
1/17/2024
Medivir AB announced further improved clinical benefit with fostrox + Lenvima® as data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma will be presented at the ASCO GI Symposium in San Francisco on January 19.
-
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer
1/11/2024
Indapta Therapeutics, Inc. today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.
-
City of Hope Research Reveals an Immune Cell That Can Attack Cancer
1/10/2024
According to preclinical research published online in Cell researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
-
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
1/10/2024
Shanghai Junshi Biosciences Co., Ltd announced the publication of results from TORCHLIGHT, a randomized, double-blind, placebo-controlled phase 3 study comparing the efficacy and safety of toripalimab versus placebo, in combination with nab-paclitaxel for patients with newly diagnosed metastatic or recurrent locally advanced triple-negative breast cancer in Nature Medicine.
-
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
1/2/2024
Shanghai Junshi Biosciences Co., Ltd announced that the supplemental new drug application (the “sNDA”) for toripalimab (trade name: TUOYI®, product code: JS001) in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (“NSCLC”) has been approved by the National Medical Products Administration.